LesionQuant Module’s Enriched Features: 3D T1 and FLAIR Reconstructed Images

An integral component of Multiple Sclerosis (MS) management is the ability to proficiently assess disease activity on MRIs from new and enlarging T2 FLAIR lesions.

The latest release of the LesionQuant module of NeuroQuant (FDA cleared, CE marked) physicians can choose to also review of spatially aligned and reconstructed images of 3D T1 and FLAIR images along slide the FLAIR color overlay images. This additional feature offers a supplemental review of lesion segmentation provided by LesionQuant.

Cortechs.ai | LesionQuant Module’s Enriched Features: 3D T1 and FLAIR Reconstructed ImagesIn addition, LesionQuant delivers fast, accurate anatomically color-coded segmented lesion images and automated FLAIR lesion and brain volume measurements compared to normative reference data. When a prior study is available, lesion change visualization and brain structure change data is available for review.

Want to learn more about LesionQuant?
We recently had a webinar to discuss the new features available in the LesionQuant from our latest software release. We also examined with case studies how the LesionQuant can help physicians quantify brain structure and lesions and as well as help in effectively evaluating disease activity in MS, based on current guidelines and research.

Our LesionQuant white paper provides more information about the accuracy and reproducibility available using LesionQuant for fully automated FLAIR lesion segmentation.

More Resources

09/30/2026

Today’s Examination Becomes Tomorrow’s Baseline: The Benefits of Performing Quantitative Analysis on Every Brain MRI

A single brain MRI shows where a patient is today. A quantitative baseline can help show how the brain changes over time.

09/18/2026

What a Head CT Can and Can’t Tell You About a Concussion

For Concussion Awareness Day, learn how quantitative CT analysis can help measure subtle structural changes and support follow-up after traumatic brain injury.

09/09/2026

Prostate Cancer Awareness Month: Finding the Cancer That Matters

How quantitative MRI can bring greater clarity to decisions across the prostate cancer journey.

09/01/2026

Quantifying What Matters: Advancing Alzheimer’s Imaging with NeuroQuant®

Explore how quantitative imaging is transforming Alzheimer’s care, from structural volumetrics and amyloid PET to treatment monitoring with NeuroQuant®.

08/19/2026

Brain Metastases Imaging Insights from SNO/ASCO 2026

Explore key insights from SNO/ASCO 2026 on brain metastases imaging, including lesion tracking, volumetric analysis, SRS workflows, and automated segmentation.

08/18/2026

Cortechs.ai Announces FDA Clearance for NeuroQuant® PET: Advancing Molecular Imaging for Cognitive Impairment

NeuroQuant® PET receives FDA 510(k) clearance, advancing quantitative PET imaging for cognitive impairment.
Scroll to Top